Comparison of Clinical Efficacy of Molecular Targeted Drugs Combined with Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemoembolization Alone for Primary Liver Cancer

Abstract

Abstract Objective: it was to explore the therapeutic value of transcatheter arterial chemoembolization (TACE) combined with molecular targeted drugs (MTD) in patients with primary liver cancer (PLC). Methods: 78 patients with PLC hospitalized in Zibo Central Hospital were randomly grouped. Group A was treated with TACE alone, group B with bevacizumab combined with TACE, and group C with sorafenib combined with TACE, 26 cases in each. The patients were followed up for 1 year, and the clinical efficacy, adverse drug reaction (ADR), laboratory indexes, and survival rate (SR) of the three groups were observed and evaluated. Results: The effective rate and disease control rate of group C were 50% and 69.23%, respectively, which were clearly higher than those of groups A (15.38%, 38.46%) and B (34.61%, 53.84%). There was no obvious distinction in serum Alpha-fetoprotein (AFP) and carcinoembryonic antigen (CEA) levels among them before treatment. Following treatment, group C (404.37±12.47 ng/mL; 246.52±38.17 ng/mL) were clearly lower than those in groups A (483.74±13.28 ng/mL, 367.28±47.03 ng/mL) and B (450.28±12.19 ng/mL, 291.72±43.69 ng/mL). The incidence of ADR in group C was generally lower than that in groups A and B, without obvious distinction in ADR of TACE among them. The overall survival time was obviously longer in group C (11.8 months) than in groups A (8.4) and B (10.1). Following 6 months of treatment, SR was not evidently different among them. Following 12 months of treatment, the SR was obviously superior in group C (84.61%) as against groups A (57.69%) and B (73.07%) (P < 0.05). Conclusion: TACE combined with MTD is superior to TACE alone in the treatment of PLC. The efficacy, survival time, and SR of sorafenib are better than those of bevacizumab.